INORegulatory•prnewswire•
INOVIO to Begin Rolling Submission of BLA for INO-3107 for the Treatment of RRP in Adults
Sentiment:Neutral (60)
Summary
Complete submission of the Biologics License Application (BLA) remains on track for 2H25 with the goal of file acceptance by U.S. Food and Drug Administration (FDA) by end of 2025 PLYMOUTH MEETING, Pa., Aug. 26, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 26, 2025 by prnewswire